A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
Suresh S. Ramalingam(Emory University), Glenwood Goss(University of Ottawa), Rafael Rosell(Institut Català d'Ornitologia), Gerald Schmid‐Bindert(Heidelberg University), Bojan Zarić(University of Novi Sad), Z. Andric(University Hospital Medical Center Bezanijska kosa), Igor Bondarenko, Д. В. Комов(Russian Academy of Sciences), Timur Cerić(University of Sarajevo), Fadlo R. Khuri(Emory University), Miroslav Samaržija(University of Zagreb), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Vera Hirsh(McGill University Health Centre), T. Wehler(Johannes Gutenberg University Mainz), James Spicer(King's College London), Ravi Salgia(University of Chicago), Geoffrey I. Shapiro(Dana-Farber Cancer Institute), Eric Sheldon(Synta Pharmaceuticals (United States)), Florentina Teofilovici(Synta Pharmaceuticals (United States)), Vojo Vukovic(Synta Pharmaceuticals (United States)), Dean A. Fennell(University of Leicester)
Cited by 108Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis